Levocarnitine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Levocarnitine
- Levocarnitine: From Undocumented Original Indication to Autosomal Dominant Familial Hematuria-Retinal Arteriolar Tortuosity-Contractures Syndrome
Levocarnitine: From Undocumented Original Indication to Autosomal Dominant Familial Hematuria-Retinal Arteriolar Tortuosity-Contractures Syndrome
One-Sentence Summary
Levocarnitine (DrugBank DB00583) has no original indication or mechanism-of-action data recorded in this evidence pack, and it is not currently marketed in the UK. The TxGNN model’s top-ranked prediction is Autosomal Dominant Familial Hematuria-Retinal Arteriolar Tortuosity-Contractures Syndrome, but this is supported by 0 clinical trials and 0 publications — the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (no licences, no original indication data) |
| Predicted New Indication | Autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for levocarnitine is not available in this evidence pack (flagged as a data gap, severity High), and no original indication is on file either — so the usual reasoning chain from “known efficacy in indication A” to “plausible efficacy in indication B” cannot be constructed here.
The predicted indication itself — a rare, inherited COL4A1-related small-vessel disorder (haematuria, retinal arteriolar tortuosity, contractures) — has no clinical trials or literature attached to it in this evidence pack. The repurposing rationale supplied alongside the prediction states plainly that this is a rare genetic vasculopathy with no trial or literature support, and that the ranking is driven purely by the TxGNN model score rather than any observed mechanistic or clinical signal.
Given the complete absence of supporting evidence and the lack of basic drug-level data (MOA, original indication), this prediction cannot currently be assessed for biological plausibility. It should be treated as an unvalidated model output rather than a reasoned hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No marketing authorisation is currently recorded for levocarnitine in this evidence pack — market status is “Not Marketed” with 0 total licences and no listed products, dosage forms, or approved indication text.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: key warnings, contraindications, and drug interaction data are all marked as data gaps in this evidence pack — most notably the missing SmPC warnings/contraindications, which is flagged as a Blocking gap that prevents even an initial safety screen.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction has no clinical trial or literature support (Evidence Level L5), and core drug-level data — original indication, mechanism of action, and SmPC safety information — are all missing or gapped. There is no basis to proceed to any safety or feasibility assessment for this specific indication.
To proceed, the following is needed:
- Original indication and mechanism-of-action data for levocarnitine (DrugBank query — data gap DG002)
- SmPC warnings/contraindications for levocarnitine (data gap DG001, Blocking — required before any S1 safety screen)
- Independent literature or preclinical rationale connecting carnitine biology to COL4A1-related vasculopathy, if this candidate is to be pursued further
Additional note: this evidence pack contains other levocarnitine-disease predictions with materially stronger evidence than the top-ranked candidate — notably rheumatoid arthritis (L2, three trials including a completed placebo-controlled Phase 2 RCT and a running Phase 2/3 programme) and congestive heart failure (L2, completed Phase 2/3 RCT with n=268, plus the established carnitine-responsive cardiomyopathy mechanism). If the goal is to identify a viable repurposing candidate for levocarnitine rather than to validate this specific top-ranked output, those two indications warrant evaluation ahead of the current rank-1 prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.